No Data
No Data
No Data
No Data
No Data
Express News | Aligos Therapeutics Inc - Alg-097558 Was Well Tolerated and Does Not Require Ritonavir Boosting
ReutersApr 25 16:27 ET
Express News | Aligos Therapeutics Presents Positive Clinical Data at Escmid 2024 From the Alg-097558 Phase 1 Study
ReutersApr 25 16:05 ET
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet
GlobeNewswireApr 25 08:00 ET
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic
GlobeNewswireApr 9 08:00 ET
Express News | Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Moomoo 24/7Apr 3 08:18 ET
Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH
Seeking AlphaApr 2 08:59 ET
No Data
No Data